Clarus Ventures’s Aerie Pharmaceuticals AERI Stock Holding History

Clarus Ventures’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-63,017	Closed	-$1.53M	–	7
2015 Q4	$1.53M	Hold	63,017	–	–	1.08%	7
2015 Q3	$1.12M	Buy	+63,017	New	+$1.14M	0.64%	8
2015 Q1	–	Sell	-3,338,067	Closed	-$97.4M	–	8
2014 Q4	$97.4M	Sell	3,338,067 -130,428	-4%	-$3.31M	27.82%	1
2014 Q3	$71.8M	Hold	3,468,495	–	–	28.63%	1
2014 Q2	$85.9M	Hold	3,468,495	–	–	30.5%	1
2014 Q1	$73.5M	Hold	3,468,495	–	–	21.27%	3
2013 Q4	$62.3M	Buy	+3,468,495	New	+$45.2M	17.6%	3

Other funds holding AERI

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Clarus Ventures's AERI Position: Q1 2016 in Review

Clarus Ventures sold out of Aerie Pharmaceuticals (AERI) in Q1 2016, closing a stake of 63,017 shares — an estimated $1.53M sold.

Clarus Ventures first reported a position in AERI in Q4 2013 and held it in 7 quarters. The position peaked at $97.4M in Q4 2014. 102 funds tracked by Wall St. Rank hold AERI as of Q1 2016.

Clarus Ventures reported no remaining Aerie Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Clarus Ventures sold 63,017 Aerie Pharmaceuticals shares in Q1 2016, an estimated $1.53M.
Clarus Ventures first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 7 quarters.
Clarus Ventures's Aerie Pharmaceuticals position peaked at $97.4M in Q4 2014.
102 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2016.

Based on Clarus Ventures's 13F filing for Q1 2016, filed 22 Apr 2016.